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Background: Immunotherapy for human hepatocellular cancer (HCC) is slowly making pro­
gress towards treating these fatal cancers. The identification of new antigens can improve this 
approach. We describe a possible new antigen, hepatocellular carcinoma­associated   antigen­519/
targeting protein for Xklp­2 (HCA519/TPX2), for HCC that might be beneficial for T­cell 
specific HCC immunotherapy.
Methods: HCC was studied for the expression for 15 tumor­associated antigens considered 
useful for immunotherapy within three HCC cell lines (HepG2, Hep3B, and PLC/PRF/5), 
lymphocytes, non­cancerous livers, and clinical HCC. The expression of tumor antigenic precur­
sor proteins (TAPPs) messenger RNA was first screened by reverse transcriptase quantitative 
real­time polymerase chain reaction.
Results: Four antigens (alpha fetoprotein, aspartyl/asparaginyl β­hydroxylase, glypican­3 and 
HCA519/TPX2) proved to be the best expressed TAPPs within the HCC specimens by molecular 
analyses. HCA519/TPX2 was detected by intracellular cell flow cytometry within HCC cell lines 
by using a specific antibody towards this TAPP. This antibody also detected the protein within 
primary HCCs. We synthesized two HCA519/TPX2 peptides (HCA519464–472 and HCA519351–359) 
which can bind to human leukocyte antigen (HLA)­A*0201. Dendritic cells pulsed with these 
peptides stimulated cytolytic T lymphocytes (CTLs). These killer T­cells lysed HLA­A*0201+ T2 
cells exogenously loaded with the correct specific peptide. The CTLs killed HepG2 (HLA­A2+ 
and HCA519+), but not the Hep3B and PLC/PRF/5 cell lines, which are HCA519+ but HLA­
A2­negative. In silico analysis reveals that HCA519/TPX2 has the inherent ability to bind to a 
very wide variety of HLA antigens.
Conclusion: HCA519/TPX2 is a viable immunotarget that should be further investigated 
within HCC patients.
Keywords: tumor immunity, cytolytic T­cells, HLA­A2, HCA519/TPX2
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers throughout 
the world; its increasing prevalence is due to chronic infections with hepatitis B or 
C viruses.1 Treatment of established HCC with standard oncological therapies remains 
ineffective, and the average survival time is just several months.2 New therapies are 
still desperately needed, especially those that focus on earlier biological/causative 
processes. Immunotherapy may be useful for future adjunct treatments of HCC.
HCC takes many years, if not decades, to appear. This time provides ample oppor­
tunity to prevent the appearance of this cancer. Immunizing children with the recombi­
nant Hepatitis (HepB) virus vaccine has significantly reduced the incidence of HCC in 
those vaccinated people in Taiwan.3 Although this HepB immunizing approach targets OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1062
aref et al
one of the HCC inducing viruses, there are no such options 
for Hepatitis C (HepC) infections. Overall, this suggests that 
HCC can be successfully abrogated, if patients are properly 
  vaccinated and this prophylactic immunity prevents the initial 
tumor cells from establishing the cancer. Previous immuno­
therapeutic attempts to treat well­established HCC have not 
been as successful,4,5 perhaps because HCC utilizes a variety 
of immunosuppressive mechanisms that prevent effective 
anti­tumor immunity. The best time to vaccinate people is 
before this cancer becomes established.   Immunoprevention 
was proposed to be more effective at a clinical level by inhib­
iting the establishment of the initial HCC clones by using 
HCC­specific antigens before HCC develops.6 A recent study 
applying the concept of immunoprevention to adenomatous 
polyps to forestall colon cancer concluded the sooner the 
vaccination began the more efficient it became.7   Vaccinations 
of chronically infected HepB or HepC individuals may pres­
ent a great opportunity to prevent HCC, provided the right 
HCC­associated antigens are used.
One of the best­known antigens for HCC is alpha feto­
protein (AFP).8 AFP is not universally expressed in all liver 
cancers.9,10 AFP is expressed during fetal development and 
may tolerize the immune system and can impede various 
immunotherapies.4,5
Aspartyl/asparaginyl β­hydroxylase (ASPH),11,12 
  glypican­3 (GPC3)13 and hepatocellular carcinoma­
  associated antigen­587 (HCA587)14,15 are being investigated 
as possible targets for HCC. HCC is reported to express 
several common antigens found on many types of cancer; 
the alternative form of macrophage colony stimulating 
factor (altM­CSF),16 B cyclin,17 carcinoembryonic antigen 
(CEA),9 N­acetylglucosaminyltransferase V (GnT­V),18 
melanoma antigen (MAGE),19,20 multidrug resistance 
protein­3 (MRP3),21 New York­Esophageal Squamous cell 
carcinoma­1 (NY­ESO­1),22 telomerase reverse transcriptase 
(tert),23 sarcoma, synovial, X­chromosome­related­2/ 
synovial sarcoma X breakpoint 2 (SSX2),19 survivin,24 and 
Wilm’s tumor antigen­1 (Wt­1).25 One HCC­associated 
antigen previously defined by a humoral response is 
HCA519.14 HCA519, also known as targeting protein for 
Xklp­2 (TPX2), is a microtubule associated protein needed 
for HCC cell division. In this paper using HCC cell lines 
and clinical samples, we conclude that HCA519/TPX2 is 
highly found within all HCC tested (n=16) and the protein 
expressions within the HCC cells are comparable to that 
exhibited by AFP, ASPH and GPC3. Peptides derived from 
HCA519/TPX2 can be recognized by human CTLs via an 
human leukocyte antigen (HLA)­A*0201 restricted manner. 
So HCA519/TPX2 should be further investigated as a good 
target for HCC immunotherapy.
Materials and methods
cell lines and cell culture
HepG2, Hep3B and PLC/PRF/5 cells were obtained from the 
American Type Culture Collection (Manassas, VA, USA). 
Peripheral­blood mononuclear cells (PBMC) from healthy 
normal HLA­A*0201+ donor were obtained after informed 
consent was signed at University of California, Irvine to gen­
erate the dendritic cells (DC) and CTLs. Frozen HLA­A2+ 
PBMC was collected from cancer patients undergoing various 
therapies at the   University of Southern California (USC) Nor­
ris Comprehensive Cancer Center (Los Angeles, CA, USA) 
in the early 2000s. These pre­HIPAA collected samples were 
supplied to us by Dr Jeffrey Weber (USC).
clinical hcc and liver tissue
This project was approved by the Veteran Affairs   Medical Cen­
ter, Long Beach Institutional Review Board before this project 
was initiated. We collected autopsy material not needed for 
diagnostic purposes. Next of kin signed the autopsy consent 
forms which allow scientific investigations to be performed 
with excess material not needed for pathological analysis. Ten 
autopsy samples were collected at our facility and the Univer­
sity of California, Irvine, Pathology Department (Irvine, CA, 
USA). The US Cooperative Human Tissue Network (CHTN, 
Vanderbilt University, Nashville, TN, USA) supplied us with 
nine other cases. Two patients were HepB­positive, while three 
were positive for HepC within our cohort.
Quantitative real-time polymerase  
chain reaction analysis 
Reverse transcriptase real­time polymerase chain reaction 
(qRT­PCR) was done as previously described.26,27 Additional 
primers for AFP, ASPH, GPC3 and HCA519 were:
•	 AFP forward: 5′­AGCCACTTGTTGCCAACTCA­3′;
	 Reverse: 5′­GCCAACACCAGGGTTTACTG­3′;
•	 ASPH forward: 5′ AGGAACAAGCAGTATATGAAC­
CTC­3′;
	 Reverse: 5′­TCCTGCTGTTCTTCCACAGG­3′
•	 GPC3 forward: 5′­ACCAAGTCCGCTCCTTCTTC­3′;
	 Reverse: 5′­GCAAATCTGATCCTGGCACG­3′;
•	 HCA519  forward: 5 ′­TTGCTCTGGCTGGA­
ATAGGG­3′;
	 Reverse: 5′­TCTGTGCGGAAGTGGAAGTC­3′.
Data is presented as the mean ∆Ct score ± standard 
error of the means. Individual groups were analyzed to be OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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  significantly different from each other using Student’s t­tests; 
P,0.05 was considered statistically significant.
antibodies
Antibodies against AFP, ASPH, GPC3, and TPX2/HCA519 
were obtained from Santa Cruz Biotech Inc., (Dallas, 
TX, USA). Cells were stained by intracellular staining as 
previously described27,28 using the antibodies against the 
HCC antigens listed. Ten thousand cells were analyzed 
with a   Becton­Dickinson Biosciences FACSCalibur™ flow 
cytometer (San Jose, CA, USA). Kolmogorov–Smirnov sta­
tistics tests showed significant differences in flow cytometry 
(P,0.05) between the experimental and isotypic controls.
Immunofluorescent staining  
of human hcc specimens
Archival HCC paraffin blocks (collected pre­HIPPA) were 
immunostained using the anti­HCA519/TPX2 antibody. The 
fluorescence images were captured using the Nikon Eclipse 
E600 fluorescence microscope system (Nikon Instruments, 
Melville, NY, USA) with the RTKE Spot Camera and Spot 
software (Diagnostic Instruments, Inc., Sterling Heights, MI, 
USA ). The levels of fluorescence expression were calculated 
by a set of parameters (area, integrated density, and mean 
gray value) from ImageJ software (National Institutes of 
Health, Bethesda, ML, USA) and expressed in average pixel 
intensity (API). Values were calculated using the formula 
(API = average integrated density – area of selected image 
mean fluorescence of background readings). Three randomly 
selected areas (100×100 pixels) per image were used to 
compare the fluorescence intensities between the various 
tissue samples.
Peptides
The sequence for HCA519/TPX2 was analyzed by 
  SYFPEITHI (http://www.syfpeithi.de/) and BIMAS (http://
www­bimas.cit.nih.gov/molbio/hla_bind/). These algorithms 
predict the strength of the peptide­major histocompatibility 
binding affinity. Peptide one, HCA519/TPX2464–472: KILEDV­
VGV , had an SYPFEITHI score for HLA­A*0201as 30 and 
BIMAS predicted this peptide had a 1,167­minute half­life 
dissociation time. Peptide two, HCA519/TPX2351–359: NLLP­
SKSSV was scored by SYFPEITHI as 26, while BIMAS 
predicted a 257 minute half­life time. Both peptides were 
synthesized by GenScript Corporation (Piscataway, NJ, 
USA). The influenza M158­66 (GILGFVFTL) peptide was 
previously made by Proimmune (Oxford, UK)26,27 served as 
the negative control.
generation of cytotoxic T lymphocytes
PBMC from a HLA­A2+ normal donor was collected and 
then used to generate CTLs as previously described.26–28 
Every 2 weeks the CTLs were restimulated with the   Miltenyi 
Biotec (Bergisch Gladback, Germany) T­cell expansion beads 
with interleukins ­2, ­7 and ­15 (PeproTech, Rocky Hill, 
NJ, USA). Cytotoxicity was done as reported earlier.26–28 
Cytolytic values were considered significantly different if 
P,0.05 was achieved using the Student’s t­test.
Results
hcc failed to express many  
of the “universal” tumor antigens
Initial studies used three human HCC cell lines, HepG2, 
Hep3B and PLC/PRF/5, and a limited number of HCC 
autopsy samples. Total RNA was extracted from those speci­
mens, and from peripheral blood lymphocytes and non­HCC 
containing livers. The last two groups provided the negative 
controls. Complementary (cDNA) was synthesized from 
those samples by using reverse transcriptase. qRT­PCR was 
performed using primers that detect various tumor antigen 
precursor proteins (TAPPs). 18S ribosomal RNA served as 
the internal control as we previously used.26,27
We first examined universal tumor antigens found on 
many cancer types such as liver, brain, lung, kidney, skin 
and other cancers.29,30 Such antigens included altM­CSF, 
B­cyclin, CEA, GnT­V , MRP3, NY­Eso­1, survivin, SSX2, 
tert, and Wt­1.   Figure 1 summarizes this data obtained from 
the experiments done with nine of these common tumor 
antigens (survivin, Wt­1, B­cyclin, CEA, MRP3, altM­CSF, 
SSX2, tert, and GnT­V). The survivin, Wt­1, and SSX2 
mRNAs were expressed at very low levels (higher ∆Ct values 
are the result of having to undergo more PCR cycles until the 
threshold was reached). The CEA and MRP3 mRNA levels 
were equivalent to those displayed by the non­cancerous 
liver or peripheral blood derived lymphocytes, which should 
be devoid of tumor­associated antigens. The only universal 
antigen that appeared significantly expressed in the HCC was 
tert. Interestingly, tert was not highly expressed within the 
HCC cell lines. Thus, HCC samples showed little expression 
of the common universal antigens.
hcc does express many  
of the HCC-specific antigens
A more restricted HCC tumor antigen profile (AFP, 
ASPH, GPC3, HCA519/TPX2, HCA587) was investigated 
 ( Figure 2). With the exception of HCA587, higher antigen OncoTargets and Therapy 2014:7
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Figure 1 qRT-PCR profiles of human TAPPs from human PBMC, HCC cell lines, non-cancerous liver and HCC tissue.
Notes: cDna from those four sources was analyzed by qrT-Pcr for (survivin, Wt-1, B-cyclin, cea, MrP3, altM-csF, ssX2, Tert and gnT-V). We took the ∆ct score of 20 
to be the reference value as 1-fold; the line drawn at a ∆ct value of 24 indicates a minimal biological response.26 l	represent the data derived from the lymphocytes; n-hcc 
cell lines; -non-cancerous liver; -HCC tissue. The numbers inside the legend box indicate how many different samples were initially analyzed. **denotes a significant 
important difference (P,0.05) between the non-cancerous liver with the hcc tissue.
Abbreviations:  altM-csF,  alternative  form  of  macrophage  colony  stimulating  factor;  cea,  carcinoembryonic  antigen;  cDna,  complementary  Dna;  hcc,  human 
hepatocellular cancer; hep, hepatocytes; gnT-V, n-acetylglucosaminyltransferase V; MrP-3, multidrug resistance protein-3; PBMc, peripheral-blood mononuclear cells; 
qrT-Pcr, real-time polymerase chain reaction; seM, standard error of the mean; ssX2, synovial sarcoma X breakpoint 2; TaPPs, tumor antigen precursor proteins; 
Tert, telomerase reverse transcriptase; Wt-1, Wilm’s tumor antigen-1.
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expression patterns were observed within the HCC compared 
to the   non­HCC samples. These four TAPP mRNAs were 
elevated within the three HCC cell lines, with ∆Ct scores 
between 11–19. These TAPPs had very low levels of mRNAs 
found within the human lymphocytes with ∆Ct scores greater 
than 23.
AFP showed the most variable phenotype of these 
four TAPPs examined. The data for only four autopsy 
samples tested are shown in the panel from the 12 total 
HCC   samples tested. Eight of these HCC displayed a ∆Ct 
score of .24, indicative of very little mRNA. All three 
HCC cell lines displayed very high levels of the AFP tran­
scripts. ASPH was detected within the lymphocytes and 
within the non­cancerous liver with ∆Ct scores slightly 
below 20,   suggesting the TAPP mRNA is moderately 
present within the normal tissue. The amount of ASPH 
mRNA coming from the HCC was lower than the values 
displayed by the HCC cell lines, since the cell lines are pure 
tumor, whereas, the clinical samples contain non­tumorous 
stromal elements.
The highest expressed TAPPs found within the HCC 
were GPC3 and HCA519. The amount of these antigens 
within the lymphocytes and normal livers was very low; 
the amount of mRNA coming from the HCC was elevated 
(P,0.05) when compared to the non­cancerous liver. 
Likewise, there was significantly more mRNA isolated 
from the HCC cell lines, when matched to the control 
lymphocytes.OncoTargets and Therapy 2014:7
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Figure 2 qRT-PCR profiles of HCC-specific TAPPs from human lymphocytes, HCC cell lines, non-cancerous liver and HCC tissue.
Notes: The cDna isolated from PBMc, hepatocellular cell lines, non-cancerous liver or hcc were subjected to qrT-Pcr analysis. l represent the data derived from 
the PBMc; n-hcc cell lines; -non-cancerous liver; -HCC tissue. The numbers inside the legend box indicate how many samples were analyzed. *denotes a significant 
difference (P,0.05) between the lymphocytes and the HCC cell lines. **denotes a significant important difference (P,0.05) between the non-cancerous liver with the hcc 
tissue.
Abbreviations: aFP, alpha fetoprotein; asPh, aspartyl/asparaginyl β-hydroxylase; cDna, complementary Dna; gPc3, glypican-3; hca519, hepatocellular carcinoma-
associated antigen-519; hca587, hepatocellular carcinoma-associated antigen-587; hcc, human hepatocellular cancer; hep, hepatocellular cells; PBMc, peripheral-blood 
mononuclear cells; qrT-Pcr, real-time polymerase chain reaction; seM, standard error of the mean; TaPPs, tumor antigen precursor proteins.
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hca519/TPX2 is not detected  
within normal tissue
Tissue was obtained from a patient who died from a cardio­
vascular event. The tissues sampled included: heart, intes­
tine, kidney, liver, lung, skeletal muscle, skin, and spleen. 
The total RNA was then examined for HCA519/TPX2 
mRNA by qRT­PCR. The spleen showed a slight amount 
of HCA519/TPX2 with a ∆Ct score of 21.1±0.0. All other 
tissues had scores .22.9, which were deemed negligible if 
any mRNA. Thus high HCA519/TPX2 mRNA expression 
only appears within HCC tissue.
hca519/TPX2 is detected  
by intracellular flow cytometry  
within the hcc cell lines
We used intracellular flow cytometry to quantitatively 
measure the amount of this HCA519/TPX2 TAPP present 
to confirm the molecular results. Figure 3 showed the three OncoTargets and Therapy 2014:7
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Figure 3 Intracellular flow cytometry of the HCA519/TPX2 TAPP found within the human HCC cell lines.
Notes: Panel (A) represents the staining profile using the antibody towards AFP. Panel (B) displays the staining profile using the anti-ASPH antibody. Panel (C) illustrates 
the staining of hca519 detected with the anti-hca519/TPX/2 antibody. Panel (D) shows the cells stained with the gPc3 antibody. One million hcc cells were stained by 
intracellular flow cytometry using the antibody towards HCA519/TPX2. The staining profile of 10,000 cells is shown. As a negative control, PBMC were used. The isotypic 
control is shown by the shaded area, while the positive staining profile is the gray line. All results with the exception of the lymphocytes showed significant differences above 
the isotypic controls (*P,0.05).
Abbreviations: aFP, alpha fetoprotein; asPh, aspartyl/asparaginyl β-hydroxylase; gPc3, glypican-3; hca519, hepatocellular carcinoma-associated antigen-519; hcc, human 
hepatocellular cancer; hep, hepatitis; PBMc, peripheral-blood mononuclear cells; seM, standard error of the mean; TaPP, tumor antigen precursor protein; TPX2, targeting 
protein for Xklp-2.
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HCC cells were significantly (P,0.05) more positive for 
HCA519/TPX2 than the control lymphocytes. These studies 
verified the previous qRT­PCR data within the clinical HCC. 
The expression of HCA519/TPX2 shows that comparable 
levels of the AFP, ASPH and GPC3 proteins were detected 
within the HCC cell lines by using their respective antibod­
ies. A slight bimodal profile was observed with the PBMC 
with all antigens. We attribute this profile to the primary or 
secondary antibodies binding to the Fc receptors found on 
the monocytes or lymphocytes present in the PBMC.
hca519/TPX2 protein is detected  
within hcc
The expression of the HCA519/TPX2 protein is less well 
known than that of AFP, ASPH and GPC3. Two randomly 
chosen archival samples of HCC were examined by immu­
nofluorescence staining using the same anti­HCA519/TPX2 
antibody that was just used for intracellular flow cytometry. 
Minimal staining of the non­cancerous liver tissue is dis­
played in Figure 4A. The two HCC cancers were positively 
stained (Figure 4B and C) with the anti­HCA519/TPX2 
antibody. Three representative fields of each sample were 
digitally quantitated and are presented in Figure 4D.
hla-a2 restricted cytolytic T-cell  
responses are induced by hca519/TPX2
We analyzed the human HCA519/TPX2 protein sequence 
by two epitope predicting algorithms (SYFPEITHI and 
BIMAS) and found two peptides that could have representa­
tive affinities for HLA­A*0201. DC from a normal HLA­
A0201+ individual was pulsed with one of the two HCA519/
TPX2 peptides overnight. The mature DC was incubated with 
autologous naïve CD8 T­cells. Once sufficient CTLs were 
expanded, they were used in standard 51Cr release assays.
The CTLs were first tested against human HLA­A*0201+ 
T2 hybridoma cells which can be loaded with exogenous OncoTargets and Therapy 2014:7
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Figure 4 Immunofluorescence of HCC as detected by HCA519/TPX2.
Notes: Two archival hcc samples were re-cut and stained using the anti-hca519/
TPX2 antibody. (A) shows normal liver that did not stain with the anti-hca519/TPX2 
antibody. (B and C) illustrate positive staining for HCA519/TPX2. All magnifications 
were taken through the 40×. (D) presents the average fluorescent intensity of the 
three different panels from representative areas of the non-cancerous liver or hcc. 
For each panel, three distinctive representative areas were imaged, the intensity 
was quantitated, and the intensity is presented ± sD. *The difference (P,0.05) in 
fluorescence of the HCC compared to the non-cancerous tissue.
Abbreviations:  hcc,  human  hepatocellular  cancer;  hca519,  hepatocellular 
carcinoma-associated antigen-519; sD, standard deviation; TPX2, targeting protein 
for Xklp-2.
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Figure 5 Human CTLs specifically kill target cells displaying HCA peptides via an 
hla-a*0201 restricted manner.
Notes: T2 cells were loaded with exogenous peptides hca519464–472 (peptide 1), 
hca519351–359 (peptide 2) or influenza M158–66 (FlU) peptide for 2 hours at 37°c 
and then radiolabeled with cr51 for 1 hour at 37°c. These washed target cells were 
incubated for 4 hours with various effectors: target ratios (50:1, 25:1 and 12:1). 
* denotes significant differences (P,0.05) of the experimental values from their 
respective control values, as typified by the responses towards the influenza peptide 
(A and B).
Abbreviations: cTls, cytolytic T lymphocytes, hca, hepatocellular carcinoma-
associated  antigen;  hca519,  hepatocellular  carcinoma-associated  antigen-519; 
hla-a, human leukocyte antigen-a; sD, standard deviation.
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peptides26,27 (Figure 5A and B). The T2 cells were loaded with 
either HCA519 peptide­1, peptide­2, or with the influenza 
M1 peptide. The HCA519464–472–specific CTLs (peptide 1) 
only killed the T2 cells exogenously loaded with the correct 
HCA519464–472 (peptide 1). Peptide 1 CTLs didn’t respond 
to T2 cells loaded with the wrong peptides (Figure 5A). 
Likewise, the HCA519351–359 CTL (peptide 2) specifically 
killed the T2 cells loaded with the appropriate HCA519351–359 
peptide (Figure 5B). Thus, these CTLs proved specific for 
their correct antigens.
The CTLs were next tested against HepG2, Hep3B, 
and PLC/PRF/5 HCC cell lines. All three HCC cell lines 
were HCA519+, but only HepG2 is HLA­A2+.8 Both 
sets of the HCA519 specific CTLs killed the HepG2 cells 
 ( Figure 6), but failed to lyse the Hep3B or PLC/PRF/5 cells. 
Thus, HepG2 cells process sufficient HCA519 peptides to 
adequately allow the CTLs to recognize them in the context 
of HLA­A*0201.
Discussion
Cell­mediated immune responses, particularly those 
induced by human DC pulsed with tumor­derived mate­
rial (killed tumor cells or peptides), are generating good 
  clinical responses for several lethal tumor types.31,32 
Therapeutic immune­based treatments are further enhanced 
against a variety of cancers, notably those that break the 
immunosuppressive pathways imposed upon the effector 
lymphocytes.33,34 DC­based vaccines have been used for 
HCC34,35 with little success, although these early studies 
were not combined with the newer methods to inhibit the 
so­called “check­point inhibitory antibodies”; ie, anti­
CTLA­4, anti­PD­1, or anti­PD­L1 antibodies. These check­
point inhibitory pathways are generating durable clinical 
responses within some patients even with moderate cancer 
burdens. For immunotherapies to work, the correct tumor 
antigens need to be recognized by the T­cells while under the OncoTargets and Therapy 2014:7
HCA519 peptide 1 CTL
Effector: target ratio
%
 
s
p
e
c
i
f
i
c
 
r
e
l
e
a
s
e
 
±
 
S
D
 
%
 
s
p
e
c
i
f
i
c
 
r
e
l
e
a
s
e
 
±
 
S
D
 
0
10
20
30
40
50
60
70
80
90
HepG2
Hep3B
PLC/PRF/5
*
*
*
HCA519 peptide 2 CTL
Effector: target ratio
0
10
20
30
40
50
60
70
80
90
HepG2
Hep3B
PLC/PRF/5
*
*
*
50:1 25:1 12:1
50:1 25:1 12:1
A
B
Figure 6 The anti-HCA519/TPX2 specific CTLs only kill HLA-A2+ hepg2 hcc 
cells.
Notes: The cTls were tested for killing against hla-a2+ and hca519+ hepg2 
cells  and  hla-a2-negative  hcc  cells  lines,  hep3B  and  Plc/PrF/5  (A  and  B). 
* denotes a P,0.05 significant difference between the killing response towards 
hepg2 from the responses towards hep3B or Plc/PrF/5.
Abbreviations: cTls, cytolytic T lymphocytes, hca, hepatocellular carcinoma-
associated  antigen;  hca519,  hepatocellular  carcinoma-associated  antigen-519; 
hcc, human hepatocellular cancer; hep,  hcc cell lines; hla-a2, human leukocyte 
antigen-a2; sD, standard deviation.
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right environmental conditions, so that the immune system 
can successfully combat the tumor. Finding more tumor­
specific antigens is therefore paramount to the success of 
this modality. In this report, we believe that HCA519/TPX2 
might be a promising tumor antigen for HCC T­cell­based 
immunotherapy.
We initially studied common universal tumor antigens that 
are widely reported to be found on many tumor types. We 
failed to find any expression of these antigens on either HCC 
cell lines and within clinical HCC samples (Figure 1). HCC­
specific antigens, AFP, ASPH, GPC3, HCA519 and HCA587 
were next examined by qRT­PCR (Figure 2).   Barring 
HCA587, we found that the HCC material expressed higher 
mRNA levels (lower ∆Ct scores) than either non­HCC liver 
tissue or lymphocytes. AFP specific transcripts were seen 
in four of the 12 samples tested, which is consistent with 
other studies that show AFP is quite variable within HCC 
patients.9,10 ASPH mRNA was highly displayed within HCC 
specimens, but unexpectedly high amounts of transcripts were 
also detected within the lymphocytes and non­cancerous 
liver. ASPH protein was not detected within the lymphocytes, 
even though they contain some mRNA (Figure 3). Otherwise 
the intracellular flow cytometry confirmed the results of the 
qRT­PCR when validated with the HCC cell lines.
HCA519/TPX2 was significantly elevated (P,0.05) 
within human HCC autopsy samples when compared to the 
livers derived from non­HCC containing livers and normal 
lymphocytes (Figure 2). HCA519 protein was detected by 
immunofluorescence within two randomly chosen HCC 
autopsy paraffin blocks from our archive (Figure 4). Using 
peptide/major histocompatibility antigen predicting data­
bases, we chose two peptides to evaluate for possible T­cell 
epitopes that could be immunologically useful for this TAPP. 
Peptides HCA519464–472 and HCA519351–359 proved effective in 
generating HLA­A*0201 restricted CTLs. These CTLs only 
killed those T2 hybridoma cells that were exogenously loaded 
with their correct peptide (Figure 5). These CTLs also lysed 
the HepG2 cells which are both HCA519+ and HLA­A0201+ 
(Figure 6). However, the CTLs didn’t kill the HCA519+ 
Hep3B or PLC/PRF/5 cells which are HLA­A2 negative. This 
work suggests that HCC cell lines properly process sufficient 
HCA519 epitopes, so that CTLs can recognize and kill HCC 
cells with the proper HLA­A2 restriction.
Half of the US general population is HLA­A2+ and 
there were 118 other possible epitopes that might induce 
human immune responses using nonamers and decamers 
of the HCA519 TAPP with SYFPEITHI scores of 16 or 
greater.   Further SYFPEITHI analysis of HCA519/TPX2 
revealed there are numerous other epitopes for the other 
HLA phenotypes. Equivalent numbers of potential epitopes 
are predicted for HLA­A11 (104), HLA­A26 (102), and 
  HLA­A68 (81). HLA­A3 had the most putative nonomer 
and decamer   peptides (187). The only haplotype that had 
few binding   peptides (28) was HLA­A24, so for Oriental 
and Western Pacific populations. HCA519/TPX2 might 
not be as effective as a target. When we examined poten­
tial peptides predicted to bind to HLA­B and HLA­DRB1 
(MHC class II), there were many possible epitopes (.100) 
available for immune recognition by both CD8+ and CD4+ 
T­cells, respectively. So even though HCA519 might not 
be useful for HLA­A24+ individuals per se, the HCA519/
TPX2 TAPP displays a high “epitope promiscuity” making 
this a possible universal vaccine for HCC. HCA519/TPX2 
is therefore a potentially immunogenic mole  cule that can be 
applicable for most people across the planet. An   alternative OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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possibility is to use this antigen to vaccinate patients who 
have a higher predilection for HCC, such as those who 
have been infected by HepB or HepC and display chronic 
infections. Since HCC takes many years to arise, there is an 
adequate opportunity to develop immunity before the cancer 
establishes itself, especially if this antigen targets a molecule 
that plays a major role in HCC cell division. As the lessons 
learned from the patients vaccinated when human adenoma­
tous polyps were detected, the sooner the vaccination began 
the more effective it became to prevent the colon cancer.7
HCA519/TPX2 associates with microtubules via kine­
tochores and facilitates aurora kinase A binding to the 
microtubules.36 Enhanced TPX2 production has also been 
associated with pancreatic37 and lung cancers.38 Studies by 
Tanaka et al39 and Yang et al40 show upregulation of TPX2 
within HCC by microarray analysis. Satow et al41 demon­
strated higher expression of HCA519/TPX2 in HCC tumor 
tissue compared to adjacent non­tumor tissue. Small interfer­
ing (siRNA)­mediated knockdown of this gene inhibited the 
proliferation of HCC cells and prevented the growth of HCC 
xenografts injected into immunodeficient mice. So this anti­
gen might be at a key spot in the HCC replication cycle, where 
immunotherapy could have an immediate effect. Even if only 
the highly expressing HCA519/TPX2+ HCC cells are killed 
by activated CTLs, then the HCC tumor cell population as a 
whole might be sufficiently reduced, thereby hindering the 
in vivo tumor growth and in turn providing the patient with a 
longer survival. Thus, HCA519/TPX2 may be developed into 
future immunotherapy for HCC, which targets a key protein 
that these cancer cells need for their proliferation.
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